^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BCL2 rearrangement

    i
    Other names: BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2
    Entrez ID:
    596
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma (ZUMA-24) (NCT05459571)
    Phase 2
    Kite, A Gilead Company
    Active, not recruiting
    Last update posted :
    06/14/2024
    Initiation :
    08/09/2022
    Primary completion :
    03/01/2026
    Completion :
    03/01/2026
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV
    Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (NCT04799275)
    Phase 2/3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/13/2024
    Initiation :
    05/20/2021
    Primary completion :
    03/01/2026
    Completion :
    03/01/2026
    BCL2 • BCL6 • CD4
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Onureg (azacitidine oral) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous
    Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (M23-647) (NCT05753501)
    Phase 1
    AbbVie
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    06/09/2023
    Primary completion :
    06/07/2027
    Completion :
    04/11/2029
    ALK • BCL2 • BCL6
    |
    ALK positive • BCL6 rearrangement • BCL2 rearrangement
    |
    ABBV-101
    Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma (NCT03223610)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    02/09/2018
    Primary completion :
    06/01/2024
    Completion :
    06/01/2025
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab) • prednisone
    Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma (19-C-0116) (NCT04002947)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/06/2024
    Initiation :
    08/05/2019
    Primary completion :
    05/31/2025
    Completion :
    03/31/2029
    ALK • BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib)
    A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND) (NCT04809467)
    Phase 1/2
    Incyte Corporation
    Active, not recruiting
    Last update posted :
    06/06/2024
    Initiation :
    09/16/2021
    Primary completion :
    12/15/2024
    Completion :
    12/15/2024
    BCL2 • CCND1 • BCL6
    |
    Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • BCL2 rearrangement
    |
    parsaclisib (INCB50465) • Monjuvi (tafasitamab-cxix)
    Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma (NCT04739813)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/06/2024
    Initiation :
    07/09/2021
    Primary completion :
    07/15/2024
    Completion :
    07/15/2029
    BCL2 • BCL6 • UGT1A1
    |
    MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • UGT1A1*1*1 • UGT1A1 mutation
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab) • prednisone • Polivy (polatuzumab vedotin-piiq)
    A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (NCT04442022)
    Phase 2/3
    Karyopharm Therapeutics Inc
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    09/03/2020
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    MYC • BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    cisplatin • gemcitabine • Rituxan (rituximab) • Xpovio (selinexor) • dexamethasone
    Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies (NCT05797233)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    08/28/2023
    Primary completion :
    12/30/2028
    Completion :
    12/30/2029
    BCL2 • BCL6
    |
    MET expression • CD20 expression • CD19 expression • BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • fludarabine IV
    Study of IMPT-314 in R/R Aggressive B-cell NHL (MPCT-012L) (NCT05826535)
    Phase 1/2
    ImmPACT Bio
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    05/09/2023
    Primary completion :
    06/01/2025
    Completion :
    12/01/2029
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    IMPT-314
    Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma (NCT06045247)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    05/29/2024
    Initiation :
    01/05/2024
    Primary completion :
    07/31/2028
    Completion :
    07/31/2030
    BCL2
    |
    MYC rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • cyclophosphamide • vincristine • prednisone • Epkinly (epcoritamab-bysp)
    Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5) (NCT04384484)
    Phase 3
    ADC Therapeutics S.A.
    Recruiting
    Last update posted :
    05/27/2024
    Initiation :
    09/16/2020
    Primary completion :
    06/30/2025
    Completion :
    06/30/2028
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • Zynlonta (loncastuximab tesirine-lpyl)
    A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT04231747)
    Phase 1
    Juno Therapeutics, a Subsidiary of Celgene
    Completed
    Last update posted :
    05/20/2024
    Initiation :
    05/21/2020
    Primary completion :
    02/01/2024
    Completion :
    02/01/2024
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • fludarabine IV • BMS-986353
    First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL (NCT04401020)
    Phase 1
    Sanofi
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    07/24/2020
    Primary completion :
    03/02/2024
    Completion :
    08/14/2024
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    SAR442257
    huCART19-IL18 in NHL/CLL Patients (NCT04684563)
    Phase 1
    University of Pennsylvania
    Recruiting
    Last update posted :
    05/13/2024
    Initiation :
    05/06/2021
    Primary completion :
    05/01/2036
    Completion :
    05/01/2036
    ALK • BCL2 • CD19 • BCL6
    |
    CD19 expression • BCL6 rearrangement • BCL2 rearrangement
    |
    huCART19 • huCART19-IL18
    Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia (NCT05869279)
    Phase 1/2
    Fondazione Matilde Tettamanti Menotti De Marchi...
    Recruiting
    Last update posted :
    05/03/2024
    Initiation :
    12/01/2023
    Primary completion :
    09/01/2026
    Completion :
    09/01/2027
    BCL2
    |
    MYC rearrangement • BCL2 rearrangement
    |
    CARCIK-CD19
    Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL (CYTB323A12101) (NCT03960840)
    Phase 1/2
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    05/03/2024
    Initiation :
    06/26/2019
    Primary completion :
    06/30/2027
    Completion :
    06/30/2027
    BCL2 • BCL6
    |
    CD19 positive • BCL6 rearrangement • BCL2 rearrangement
    |
    Imbruvica (ibrutinib) • rapcabtagene autoleucel (YTB323)
    Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (DALY 2-EU) (NCT04844866)
    Phase 2
    Miltenyi Biomedicine GmbH
    Recruiting
    Last update posted :
    04/30/2024
    Initiation :
    08/18/2021
    Primary completion :
    12/31/2024
    Completion :
    07/31/2027
    BCL2 • CD19 • BCL6
    |
    CD19 expression • BCL6 rearrangement • BCL2 rearrangement
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • bendamustine • Polivy (polatuzumab vedotin-piiq) • zamtocabtagene autoleucel (MB-CART2019.1)
    Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1) (NCT03870945)
    Phase 1/2
    Miltenyi Biomedicine GmbH
    Active, not recruiting
    Last update posted :
    04/30/2024
    Initiation :
    02/25/2019
    Primary completion :
    12/17/2020
    Completion :
    12/31/2025
    BCL2 • BCL6
    |
    CD19 expression • BCL6 rearrangement • BCL2 rearrangement
    |
    zamtocabtagene autoleucel (MB-CART2019.1)
    Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma (NCT03696784)
    Phase 1
    UNC Lineberger Comprehensive Cancer Center
    Recruiting
    Last update posted :
    04/26/2024
    Initiation :
    03/12/2019
    Primary completion :
    03/22/2027
    Completion :
    03/22/2043
    ALK • BCL2 • BCL6 • IRF4
    |
    ALK positive • BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD) • cyclophosphamide intravenous • rimiducid (AP1903)
    Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. (NCT04223765)
    Phase 1
    UNC Lineberger Comprehensive Cancer Center
    Recruiting
    Last update posted :
    04/23/2024
    Initiation :
    11/12/2020
    Primary completion :
    03/22/2028
    Completion :
    03/22/2043
    ALK • BCL2 • BCL6 • IRF4
    |
    ALK positive • BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • fludarabine IV • Belrapzo (bendamustine RTD) • cyclophosphamide intravenous
    Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma (NCT03681535)
    Phase N/A
    Duke University
    Active, not recruiting
    Last update posted :
    04/22/2024
    Initiation :
    02/13/2019
    Primary completion :
    08/01/2025
    Completion :
    08/01/2028
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL (NCT04594798)
    Phase 2
    University of Rochester
    Recruiting
    Last update posted :
    04/16/2024
    Initiation :
    09/20/2021
    Primary completion :
    07/31/2024
    Completion :
    07/31/2024
    MYC • BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • cyclophosphamide intravenous
    A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM) (NCT03310619)
    Phase 1/2
    Celgene
    Completed
    Last update posted :
    04/04/2024
    Initiation :
    12/20/2017
    Primary completion :
    02/15/2023
    Completion :
    02/15/2023
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Opdivo (nivolumab) • Imfinzi (durvalumab) • Imbruvica (ibrutinib) • Breyanzi (lisocabtagene maraleucel) • avadomide (CC-122) • iberdomide (CC-220) • relatlimab (BMS-986016) • golcadomide (CC-99282)
    Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas (NCT05583149)
    Phase 2
    Patrick C. Johnson, MD
    Recruiting
    Last update posted :
    04/04/2024
    Initiation :
    03/01/2023
    Primary completion :
    03/01/2025
    Completion :
    03/01/2029
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • Calquence (acalabrutinib) • Breyanzi (lisocabtagene maraleucel) • fludarabine IV
    Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy (NCT05065866)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    04/02/2024
    Initiation :
    11/18/2021
    Primary completion :
    03/01/2024
    Completion :
    03/01/2025
    ALK • MYC • BCL2 • CD8 • TNFRSF8 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Copiktra (duvelisib) • Onureg (azacitidine oral)
    A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) (CRC-403) (NCT05169489)
    Phase 1/2
    2seventy bio
    Recruiting
    Last update posted :
    04/01/2024
    Initiation :
    01/24/2022
    Primary completion :
    08/01/2024
    Completion :
    08/01/2025
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    bbT369
    TmCD19-IL18 in CD19+ Cancers (NCT05989204)
    Phase 1
    University of Pennsylvania
    Recruiting
    Last update posted :
    04/01/2024
    Initiation :
    11/13/2023
    Primary completion :
    10/01/2026
    Completion :
    10/01/2041
    ALK • BCL2 • CD19 • BCL6
    |
    CD19 expression • BCL6 rearrangement • BCL2 rearrangement
    |
    huCART19-IL18
    Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma (NCT05852717)
    Phase 2
    Dipenkumar Modi
    Recruiting
    Last update posted :
    03/29/2024
    Initiation :
    10/31/2023
    Primary completion :
    06/01/2024
    Completion :
    06/01/2025
    ALK • MYC • BCL2 • CD20 • BCL6 • CD4
    |
    ALK positive • BCL6 rearrangement • BCL2 rearrangement
    |
    cisplatin • gemcitabine • dexamethasone • Epkinly (epcoritamab-bysp)
    Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) (NCT02631044)
    Phase 1
    Juno Therapeutics, a Subsidiary of Celgene
    Active, not recruiting
    Last update posted :
    03/27/2024
    Initiation :
    01/06/2016
    Primary completion :
    05/10/2024
    Completion :
    05/10/2024
    BCL2 • CCND1 • BCL6
    |
    CD19 positive • Chr t(11;14) • BCL6 rearrangement • CCND1 expression • BCL2 rearrangement
    |
    Breyanzi (lisocabtagene maraleucel)
    A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma (NCT04313608)
    Phase 1
    Hoffmann-La Roche
    Completed
    Last update posted :
    03/25/2024
    Initiation :
    06/04/2020
    Primary completion :
    10/26/2021
    Completion :
    10/26/2021
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    gemcitabine • Gazyva (obinutuzumab) • oxaliplatin • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm)
    Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA) (NCT03570892)
    Phase 3
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    03/22/2024
    Initiation :
    05/07/2019
    Primary completion :
    02/13/2026
    Completion :
    02/14/2026
    ALK • BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • Kymriah (tisagenlecleucel-T)
    Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma (NCT04479267)
    Phase 2
    Barbara Ann Karmanos Cancer Institute
    Recruiting
    Last update posted :
    03/20/2024
    Initiation :
    08/21/2020
    Primary completion :
    11/15/2025
    Completion :
    11/15/2026
    MYC • BCL2 • BCL6
    |
    MYC overexpression • MYC expression • BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • cyclophosphamide intravenous • methylprednisolone sodium succinate • prednisolone
    A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia (NCT04307576)
    Phase 3
    Mats Heyman
    Recruiting
    Last update posted :
    03/19/2024
    Initiation :
    07/13/2020
    Primary completion :
    06/30/2027
    Completion :
    06/30/2032
    MYC • BCL2 • KMT2A
    |
    MYC rearrangement + BCL2 rearrangement • MLL rearrangement • MYC rearrangement • MYC translocation • BCL2 rearrangement
    |
    imatinib • doxorubicin hydrochloride • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • vincristine • thioguanine
    Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL (NCT05554939)
    Phase 1/2
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    03/15/2024
    Initiation :
    12/11/2022
    Primary completion :
    12/31/2025
    Completion :
    12/31/2026
    BCL2 • CCND1 • BCL6
    |
    CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
    |
    cyclophosphamide • fludarabine IV • Mustargen (mechlorethamine)
    Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NCT06005649)
    Phase 1/2
    Juventas Cell Therapy Ltd.
    Not yet recruiting
    Last update posted :
    03/08/2024
    Initiation :
    08/31/2024
    Primary completion :
    12/01/2024
    Completion :
    09/01/2026
    BCL2 • BCL6 • IL6 • CD22
    |
    CD19 positive • BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • HY004
    Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7) (NCT03391466)
    Phase 3
    Kite, A Gilead Company
    Active, not recruiting
    Last update posted :
    03/07/2024
    Initiation :
    01/25/2018
    Primary completion :
    03/18/2021
    Completion :
    10/01/2024
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement • CD20 negative
    |
    carboplatin • cytarabine • cyclophosphamide • oxaliplatin • Yescarta (axicabtagene ciloleucel) • fludarabine IV • cyclophosphamide intravenous • methylprednisolone sodium succinate
    Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT04586478)
    Phase 2
    Juventas Cell Therapy Ltd.
    Recruiting
    Last update posted :
    03/06/2024
    Initiation :
    10/26/2020
    Primary completion :
    06/30/2024
    Completion :
    09/30/2025
    BCL2 • BCL6
    |
    CD19 positive • BCL6 rearrangement • BCL2 rearrangement • CD20 negative
    |
    cyclophosphamide • fludarabine IV • Yuanruida (inaticabtagene autoleucel)
    Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma (NatHaLi-01) (NCT05607420)
    Phase 1/2
    Cellectis S.A.
    Recruiting
    Last update posted :
    03/01/2024
    Initiation :
    11/01/2022
    Primary completion :
    11/01/2027
    Completion :
    11/01/2027
    BCL2 • BCL6 • CD22
    |
    CD20 positive • BCL6 rearrangement • BCL2 rearrangement
    |
    Campath (alemtuzumab) • UCART20x22
    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia (NCT03104491)
    Phase 1/2
    Leland Metheny
    Recruiting
    Last update posted :
    02/29/2024
    Initiation :
    07/31/2017
    Primary completion :
    05/01/2024
    Completion :
    05/01/2026
    BCL2 • BCL6 • CD22
    |
    BCL6 rearrangement • CD22 positive • BCL2 rearrangement
    |
    Besponsa (inotuzumab ozogamicin)
    DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL (HOVON-152) (NCT03620578)
    Phase 2
    Stichting Hemato-Oncologie voor Volwassenen Ned...
    Active, not recruiting
    Last update posted :
    02/14/2024
    Initiation :
    08/01/2018
    Primary completion :
    01/30/2024
    Completion :
    10/01/2026
    PD-L1 • BCL2 • BCL6
    |
    MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement
    |
    Opdivo (nivolumab)